-

Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2025 financial results on Wednesday, August 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 6th, at 9:00 a.m. ET.

Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Contacts

Investor Relations Contact:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

Charles River Laboratories International, Inc.

NYSE:CRL

Release Summary
Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call
Release Versions

Contacts

Investor Relations Contact:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

More News From Charles River Laboratories International, Inc.

Charles River Laboratories Announces Second-Quarter 2025 Results

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Second-Quarter 2025 Results...

Charles River and BioTech Social Inc. Pursue Crowdfunding Partnership

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River announced the exploration of a potential collaboration to provide CIP/CAP participants access the BioTech Funding Portal....

Charles River Joins Elly’s Team to Drive Rare Disease Gene Therapy Development

WILMINGTON, Mass.--(BUSINESS WIRE)--As part of Charles River’s Cell & Gene Therapy Accelerator Program, Elly’s Team manufactured critical starting materials for a Phase I clinical trial....
Back to Newsroom